Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

H3 receptor blockade with GT-2227 increases wakefulness without subsequent hypersomnolence

July 17, 1998

BIBN-99 improves cognition independent of effects on sleep

July 17, 1998

Cambridge NeuroScience and Boehringer Ingelheim end Cerestat collaboration

July 17, 1998

Venlafaxine relieves anxiety; more cost-effective than other antidepressants

July 16, 1998

Lilly team claims metabotropic glutamate receptor antagonists

July 16, 1998

CNS compounds from ADIR that selectively bind to D4 receptors

July 16, 1998

Phase II clinical trial begins for fibromyalgia treatment

July 16, 1998

Risperidone: satellite symposia discuss impact on cognition and behavior

July 16, 1998

Pfizer reports pharmacokinetics of a novel anxiolytic agent - CP-93393

July 16, 1998

M-100907 improves positive and negative symptoms and is well tolerated in schizophrenics

July 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...